首页> 外国专利> METHOD OF TREATMENT OF ISOLATED SYSTOLIC ARTERIAL HYPERTENSION OF 1 DEGREE IN PATIENTS IN EARLY PERIOD OF OLD AND SENILE AGE

METHOD OF TREATMENT OF ISOLATED SYSTOLIC ARTERIAL HYPERTENSION OF 1 DEGREE IN PATIENTS IN EARLY PERIOD OF OLD AND SENILE AGE

机译:老年患者早期收缩性孤立性1例高血压的治疗方法

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to therapy, cardiology and clinical pharmacology, and can be used for treating isolated degree 1 systolic arterial hypertension (ISAH) in patients of early period of old age - 65–74 years and senile age - older than 75 years. In all patients with ISAH 1 degree of the above age, molecular diagnostics of blood plasma is performed and the level of expression of cathepsin G, myeloperoxidase, induced hypoxia Ia, hyaluronidase, kininogen-1, pyruvate kinase and subunit of alpha ATP-synthase. In the senile age, the level of expression of apolipoprotein D, a transforming growth factor beta-1, fibulin-5 is additionally determined. If observing the presence of a level of expression of cathepsin G equal to 3.5 ng/ml or more, myeloperoxidase, equal to 23 Un/ml or more, hypoxia of the induced factor Ia equal to 280 pg/ml or more, hyaluronidase equal to 9 mE/l or more, kininogen-1 equal to 85 ng/ml or more, pyruvate kinase equal to 10 Un/ml or more, and subunit of alpha ATP-synthase equal to 60 pg/ml or more, apolipoprotein D, equal to or greater than 30 ng/ml, transforming growth factor beta-1 equal to 900 pg/ml or more, fibulin-5 equal to 250 pg/ml or more, therapy is ensured by prescribing a combination of the blocker to the angiotensin II receptor and the slow calcium channel blocker.;EFFECT: method provides reducing the dose of hypotensive medicines, increasing the effectiveness and safety of the treatment while reducing the economic costs of the pharmacotherapy by using the antihypertensive drugs taking into account the molecular profile of the blood plasma in each patient.;1 cl, 2 ex
机译:领域:药物;发明:本发明涉及医学,即治疗,心脏病学和临床药理学,可用于治疗65岁至74岁的早期老年患者的单纯1级收缩期动脉高压(ISAH)。老年-超过75岁。在所有年龄在ISAH 1以上的患者中,进行血浆分子诊断,并检测组织蛋白酶G,髓过氧化物酶,诱导的缺氧Ia,透明质酸酶,激肽原1,丙酮酸激酶和αATP合酶亚基的表达水平。在老年期,还确定了载脂蛋白D(一种转化生长因子β-1,fibulin-5)的表达水平。如果观察到组织蛋白酶G的表达水平等于或大于3.5 ng / ml,髓过氧化物酶等于或等于23 Un / ml,诱导因子Ia的低氧等于或大于280 pg / ml,透明质酸酶等于9 mE / l或更高,激肽原-1等于或等于85 ng / ml,丙酮酸激酶等于或等于10 Un / ml或更高,并且αATP合酶的亚基等于或超过60 pg / ml,载脂蛋白D等于达到或大于30 ng / ml,转化生长因子β-1等于或大于900 pg / ml,纤维蛋白5等于或大于250 pg / ml,通过将阻断剂与血管紧张素II处方开方确保治疗效果:该方法可降低降压药的剂量,提高治疗的有效性和安全性,同时考虑到血液的分子特征,通过使用降压药降低药物治疗的经济成本每个病人的血浆。; 1 cl,2 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号